**Velphoro was well tolerated with long-term use*¹**

GI adverse events were mild to moderate, and resolved without intervention¹

Adverse events occurring in >5% of patients during the 52-week clinical study^1,2:

Diarrhea (24%): The majority of diarrhea events were mild and transient, occurred soon after initiation of treatment, and resolved¹

See time to onset
Discolored feces (16%): Discolored feces is expected with an iron-containing product¹
Nausea (10%): Incidences were reported during the first 6 months, but diminished over time²

Velphoro is selective, with few drug or metabolic interactions

Velphoro is a powerful, selective phosphate binder that doesn't bind to vitamins A, D, E, K, or folic acid, as sevelamer does.^1,3

Patients taking Velphoro require no additional monitoring for iron management

The iron in Velphoro is not absorbed. Nearly all of it binds to phosphate¹
No additional monitoring of iron indices needed¹
Velphoro has no contraindications, and does not contribute to iron overload syndrome¹

INDICATION

Velphoro^® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451